These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33852535)

  • 41. Diagnosis and staging of cardiac masses: additional value of CMR with
    Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
    Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
    Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
    J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
    Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
    Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
    Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Predictive value of positron emission tomography with 18F-FDG in the diagnosis and staging of patients with Hodgkin's lymphoma].
    Khodzhibekova MM
    Vopr Onkol; 2013; 59(4):470-4. PubMed ID: 24032221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 51. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.
    Hernandez-Pampaloni M; Takalkar A; Yu JQ; Zhuang H; Alavi A
    Pediatr Radiol; 2006 Jun; 36(6):524-31. PubMed ID: 16622665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies.
    Bucerius J; Herkel C; Joe AY; Altehoefer C; Finke J; Moser E; Reinhardt MJ
    Nuklearmedizin; 2006; 45(3):105-10; quiz N25-6. PubMed ID: 16710505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Whole-Body Diffusion-Weighted MRI Compared to
    Shapira-Zaltsberg G; Wilson N; Trejo Perez E; Abbott L; Dinning S; Kapoor C; Davila J; Smith B; Miller E
    Can Assoc Radiol J; 2020 May; 71(2):217-225. PubMed ID: 32062992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
    Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
    Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
    Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.